Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Head and neck cancer patient-derived xenograft models - A systematic review

Full text
Author(s):
Schuch, Lauren F. [1] ; Silveira, Felipe M. [1] ; Wagner, Vivian P. [1] ; Borgato, Gabriell B. [1] ; Rocha, Guilherme Z. [1] ; Castilho, Rogerio M. [2, 3] ; Vargas, Pablo A. [1] ; Martins, Manoela D. [1, 4]
Total Authors: 8
Affiliation:
[1] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Oral Diag, Piracicaba, SP - Brazil
[2] Univ Michigan, Sch Dent, Lab Epithelial Biol, Dept Periodont & Oral Med, Ann Arbor, MI 48109 - USA
[3] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 - USA
[4] Univ Fed Rio Grande do Sul, Sch Dent, Dept Oral Pathol, Porto Alegre, RS - Brazil
Total Affiliations: 4
Document type: Review article
Source: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY; v. 155, NOV 2020.
Web of Science Citations: 0
Abstract

Background: Patient-derived xenograft (PDX) involve the direct surgical transfer of fresh human tumor samples to immunodeficient mice. This systematic review aimed to identify publications of head and neck cancer PDX (HNC-PDX) models, describing the main methodological characteristics and outcomes. Methods: An electronic search was undertaken in four databases, including publications having used HNC-PDX. Data were analyzed descriptively. Results: 63 articles were yielded. The nude mouse was one most commonly animal model used (38.8 %), and squamous cell carcinoma accounted for the majority of HNC-PDX (80.6 %). Tumors were mostly implanted in the flank (86.3 %), and the latency period ranged from 30 to 401 days. The successful rate ranged from 17 % to 100 %. Different drugs and pathways were identified. Conclusion: HNC-PDX appears to significantly recapitulate the morphology of the original HNC and represents a valuable method in translational research for the assessment of the in vivo effect of novel therapies for HNC. (AU)

FAPESP's process: 16/21785-4 - Association of BDNF/TRKB signaling pathway with tumor agressiveness and cancer stem cell profile of malignant salivary gland tumors
Grantee:Vivian Petersen Wagner
Support Opportunities: Scholarships in Brazil - Post-Doctoral